Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1111/j.1365-4632.2004.02501.x
10.1111/j.1365-4632.2004.02501.x · External reference
10.1016/s0140-6736(17)30070-3
10.1016/s0140-6736(17)30070-3 · External reference
10.1001/jamadermatol.2023.5679
10.1001/jamadermatol.2023.5679 · External reference
10.1001/jamadermatol.2019.3236
10.1001/jamadermatol.2019.3236 · External reference
Longitudinal trends in immunological biomarkers, and predictors of relapse in pemphigus treated with rituximab: a prospective cohort study
2025 · External reference
10.1001/jamadermatol.2024.6130
10.1001/jamadermatol.2024.6130 · External reference
10.1111/ijd.16363
10.1111/ijd.16363 · External reference
Rituximab – Progress but still not a final resolution for pemphigus patients: clinical report from a single center study
10.3389/fimmu.2022.884931 · 2022 · External reference
10.1172/jci.insight.92021
10.1172/jci.insight.92021 · External reference
10.1002/eji.201646782
10.1002/eji.201646782 · External reference
10.1016/j.jaci.2012.03.022
10.1016/j.jaci.2012.03.022 · External reference
Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters
10.1172/jci166357 · 2023 · External reference
A comprehensive review on the efficacy of anti‐CD20 therapies in pemphigus treatment
2024 · External reference
10.1016/j.jdcr.2020.05.034
10.1016/j.jdcr.2020.05.034 · External reference
10.1007/s00415-023-12007-3
10.1007/s00415-023-12007-3 · External reference
10.1016/j.jdin.2025.05.018
10.1016/j.jdin.2025.05.018 · External reference
10.1016/j.jdcr.2021.08.005
10.1016/j.jdcr.2021.08.005 · External reference
10.1016/j.jdcr.2022.07.011
10.1016/j.jdcr.2022.07.011 · External reference
10.1001/jamadermatol.2014.1939
10.1001/jamadermatol.2014.1939 · External reference
10.1517/13543780902832679
10.1517/13543780902832679 · External reference
10.1111/bjd.15947
10.1111/bjd.15947 · External reference
10.1007/s12325-016-0451-1
10.1007/s12325-016-0451-1 · External reference
Successful treatment of pemphigus vulgaris with ofatumumab
2018 · External reference
The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database
10.3389/fimmu.2025.1537334 · 2025 · External reference
The role of B cell‐activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
10.3389/fimmu.2025.1538555 · 2025 · External reference
Modifications of the BAFF/BAFF‐receptor Axis in patients with pemphigus treated with rituximab versus standard corticosteroid regimen
10.3389/fimmu.2021.666022 · 2021 · External reference
BLyS/APRIL dual inhibition by telitacicept for refractory pemphigus vulgaris combined with hepatocellular cancer
10.1016/j.abd.2025.501263 · 2026 · External reference
10.1093/bjd/ljaf023
10.1093/bjd/ljaf023 · External reference
10.1056/nejmoa2414719
10.1056/nejmoa2414719 · External reference
10.1007/s10067-024-07266-y
10.1007/s10067-024-07266-y · External reference
POS0535 comparison of telitacicept and belimumab in patients with SLE
10.1136/annrheumdis-2024-eular.3775 · 2024 · External reference
Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta‐analysis
10.1038/s41598-025-29929-9 · 2025 · External reference
10.1016/j.ard.2025.11.015
10.1016/j.ard.2025.11.015 · External reference
10.2147/dddt.s114552
10.2147/dddt.s114552 · External reference
10.1038/jid.2009.27
10.1038/jid.2009.27 · External reference
Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus
10.3389/fmed.2021.708071 · 2021 · External reference
10.1111/bjd.20431
10.1111/bjd.20431 · External reference
10.1016/j.jid.2024.02.023
10.1016/j.jid.2024.02.023 · External reference
10.1016/j.jdermsci.2021.07.002
10.1016/j.jdermsci.2021.07.002 · External reference
Pemphigus vulgaris treated with ibrutinib: a case report
2024 · External reference
10.1056/nejmoa2110297
10.1056/nejmoa2110297 · External reference
10.3390/jcm14196774
10.3390/jcm14196774 · External reference
Binding to the neonatal fc receptor enhances the pathogenicity of anti‐desmoglein‐3 antibodies in keratinocytes
10.3389/fimmu.2024.1473637 · 2024 · External reference
10.1111/bjd.20782
10.1111/bjd.20782 · External reference
Unresolved reference
2023 · External reference
10.1126/science.aaf6756
10.1126/science.aaf6756 · External reference
10.1172/jci138416
10.1172/jci138416 · External reference
Unresolved reference
External reference
Antigen‐fc fusion therapy reduces severity of a model of pemphigus vulgaris without systemic immunosuppression
10.1126/scitranslmed.adk6484 · 2025 · External reference
Targeting CD38 with daratumumab in refractory systemic lupus erythematosus
10.1056/nejmoa2023325 · 2020 · External reference
FcRn antagonism leads to a decrease of desmoglein‐specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphiggus foliaceus
10.3389/fimmu.2022.863095 · 2022 · External reference
10.1016/j.jaut.2018.03.003
10.1016/j.jaut.2018.03.003 · External reference
Peripheral tolerance by Treg via constraining OX40 signal in autoreactive T cells against desmoglein 3, a target antigen in pemphigus
10.1073/pnas.2026763118 · 2021 · External reference
Unresolved reference
2017 · External reference
10.1093/bjd/ljaf311
10.1093/bjd/ljaf311 · External reference
10.1074/jbc.m109.087999
10.1074/jbc.m109.087999 · External reference
10.1073/pnas.0602973103
10.1073/pnas.0602973103 · External reference
10.1371/journal.pone.0119809
10.1371/journal.pone.0119809 · External reference
